الصفحة الرئيسية>>Signaling Pathways>> Apoptosis>>Isatuximab

Isatuximab

رقم الكتالوجGC63386 Copy One-Click Copy Product Info

Isatuximab هو جسم مضاد أحادي النسيلة يستهدف مستقبل الغشاء و ectoenzyme CD38 ، وهو بروتين يتم التعبير عنه بشكل كبير في الخلايا الخبيثة الدموية ، بما في ذلك تلك الموجودة في المايلوما المتعددة (MM)يحتوي Isatuximab على نشاط مضاد للورم عبر آليات بيولوجية متعددة ، بما في ذلك السمية الخلوية المعتمدة على الجسم المضاد ، والسمية الخلوية المعتمدة على المكمل ، والبلعمة الخلوية المعتمدة على الجسم المضاد ، والحث المباشر لموت الخلايا المبرمج دون الارتباط المتشابكيثبط Isatuximab أيضًا نشاط الإنزيم الخارجي CD38 بشكل مباشر ، وهو متورط في العديد من الوظائف الخلوية

Products are for research use only. Not for human use. We do not sell to patients.

Isatuximab التركيب الكيميائي

Cas No.: 1461640-62-9

الحجم السعر المخزون الكميّة
1 mg
315٫00
متوفر
5 mg
774٫00
متوفر
10 mg
1305٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com


مراجعات العميل

بناء على آراء العملاء.

Sample solution is provided at 25 µL, 10mM.



Description of Isatuximab

Isatuximab is a monoclonal antibody targeting the transmembrane receptor and ectoenzyme CD38, a protein highly expressed on hematological malignant cells, including those in multiple myeloma (MM). Isatuximab has antitumor activity via multiple biological mechanisms, including antibody-dependent cellular-mediated cytotoxicity, complement-dependent cytotoxicity, antibody-dependent cellular phagocytosis, and direct induction of apoptosis without crosslinking. Isatuximab also directly inhibits CD38 ectoenzyme activity, which is implicated in many cellular functions[1][2].

An in-vitro study shows that the combination of Isatuximab with Pomalidomide (an immunomodulatory drug) results in greater direct toxicity and lysis of CD38 multiple myeloma cells by effector cells compared with Isatuximab alone[2].

[1]. Dhillon S. Isatuximab: First Approval [published correction appears in Drugs. 2020 May 23;:]. Drugs. 2020;80(9):905-912.
[2]. Attal M, et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study [published correction appears in Lancet. 2019 Dec 7;394(10214):2072]. Lancet. 2019;394(10214):2096-2107.

Chemical Properties of Isatuximab

Cas No. 1461640-62-9 SDF
Formula M.Wt
الذوبان Storage Store at 4°C, do not freeze
General tips Please select the appropriate solvent to prepare the stock solution according to the solubility of the product in different solvents; once the solution is prepared, please store it in separate packages to avoid product failure caused by repeated freezing and thawing.Storage method and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored at -20°C, please use it within 1 month.
To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time.
Shipping Condition Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request.
  • حاسبة المولارية

  • حاسبة التخفيف

  • Molecular Weight Calculator

كتلة
=
تركيز
x
مقدار
x
ميغاواط *
 
 
 
** عند إعداد حلول المخزون، دائمًا استخدم الوزن الجزيئي الخاص بالدفعة للمنتج على ملصق القارورة MSDS / CoA (متوفر عبر الإنترنت).

احسب

In vivo Formulation Calculator (Clear solution) of Isatuximab

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % saline
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.

Product Documents of Isatuximab

Quality Control & SDS

View current batch:

مراجعات

Review for Isatuximab

Average Rating: 5 ★★★★★ (Based on Reviews and 6 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%